Business Wire

The Flemish Government Selects DXC to Help Drive Transformation of Public Services

Share

DXC Technology (NYSE: DXC) announced today that it has been awarded a new 7-year IT services agreement extension by the Flemish Government, to continue supporting the Government’s transformation journey and efforts to respond to citizens’ needs through innovative and reliable public services. As the volume of transactions increases with more consumer-driven demands for information, DXC will help the Flemish Government to lower total costs and improve mainframe operations, security, performance, capacity and processing efficiency.

DXC’s expertise and capabilities across the Enterprise Technology Stack will enable DXC to build, run and operate modern application services in a hybrid cloud infrastructure for the Flemish Government. The goal is to l simplify the work of the public sector and support the Government to provide efficient, safe and easy-to-use digital public services, re-imagine the customer experience for citizens and businesses, and deliver more effectively on the public’s needs.

The contract extension is an opportunity for DXC to continue to deliver excellence and build on recent successful projects that Flanders citizens really care about; such as the “Corona Hinderpremie” for processing payment claims as well as “Vaccinnet”, a program for ordering vaccines in the health sector which DXC supported with training and user adoption to ensure a timely launch.

The Flemish Government and DXC have been working together for 18 years on diverse public sector projects and the contract extension reaffirms the strong relationship and confidence the Government has in the new DXC as a reliable IT partner.

Barbara Van Den Haute, administrateur-generaal at the Flemish Government: “We are focused on the modernisation of our public services and are glad to continue that work in collaboration with DXC Technology. We are striving to push forward, together, our IT transformation to develop innovative projects that will improve, simplify, and accelerate our services for citizens, businesses, and associations; should they be related to health, environmental or economic issues.”

“The Government of Flanders is a valued DXC customer. We are thrilled to extend our collaboration for the next seven years, bringing to bear our capabilities across the Enterprise Technology Stack in order to help the Flemish Government realize their strategic ambitions,” said Steve Turpie, Senior VP—EMEA, DXC Technology. ”We are committed to the Government’s program and to deliver innovative, cost-effective and timely technology solutions to the business community and citizens.”

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Antonio Carril, Marketing & Communications, Belux, +32476228587, antonio.carril@dxc.com
Louise Preedy , Marketing & Communications, Southern Europe, lpreedy@dxc.com
Antoine Roussel , Marketing & Communications, Southern Europe, aroussel@dxc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LambdaTest Integrates with Assembla to Streamline Bug Tracking for Development Teams3.6.2025 18:00:00 EEST | Press release

LambdaTest, a unified agentic AI and cloud engineering platform, has announced its partnership with Assembla, a robust cloud-based platform for version control and project management. This collaboration enables software development teams to streamline their bug tracking processes and improve overall productivity. LambdaTest offers developers an exhaustive list of cloud-based testing solutions, including cross-browser compatibility testing, Web and App automation testing, and Real Device testing. Assembla users can now easily integrate with the LambdaTest platform to seamlessly mark bugs with detailed screenshots and assign them to team members. "This integration between LambdaTest and Assembla allows development teams to optimize their testing and bug tracking processes," said Mayank Bhola, Co-Founder and Head of Product at LambdaTest. "By connecting these platforms, teams can maintain uninterrupted workflow while ensuring thorough documentation and tracking of issues discovered during

The Future of AI in the AEC Industry Unveiled at BST Global’s 2025 AI Summit3.6.2025 17:41:00 EEST | Press release

BST Global, the leading provider of AI-powered project intelligence™ solutions for the AEC industry, hosted its second annual AI Summit, May 6–8, 2025, in Palm Beach, FL. The premier event brought together 12 thought leaders from some of the world’s most influential firms, including Arcadis, Arup, AtkinsRéalis, Gensler, GHD, Jacobs, Mott MacDonald, NVIDIA, Parsons, Stantec, and WSP to share insights on how AI is reshaping the future of the AEC industry. Attendees as well as the broader AEC community praised the 2025 AI Summit for its timely content and line-up of industry trailblazers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603538561/en/ BST Global Chief Executive Officer Javier A. Baldor officially kicks off the AI Summit’s first full day of sessions by presenting his perspective on the driving forces impacting the AEC industry and the world at large. He shares three key ways AI and big data will transform nearly

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 20253.6.2025 17:30:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced that data from numerous programs in its hematology/oncology portfolio will be presented at the 2025 European Hematology Association (EHA) congress, held June 12 – 15, 2025, in Milan. "We're looking forward to presenting new data from across our hematology/oncology portfolio at the 2025 EHA Congress, including late-breaking data for our first in class, mutCALR-directed monoclonal antibody, INCA033989,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “We believe the data that will be presented at the late-breaking session demonstrate the impact of the novel mechanism of action of this monoclonal antibody against mutCALR-driven essential thrombocythemia (ET), and support its potential to be a disease modifying agent and thus transform the treatment of patients with myeloproliferative neoplasms (MPNs) like essential thrombocythemia (ET)." Key Incyte abstracts accepted for presentation at EHA include: Late-Breaking Or

European Commission Approves ADCETRIS ® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD3.6.2025 17:12:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025. The approval for this ADCETRIS-based combination regimen, known as BrECADD, in frontline Hodgkin lymphoma is based on the results of the randomized Phase 3 HD21 trial. The study met its co-primary safety and efficacy endpoints, with BrECADD demonstrating significantly superior safety as assessed by treatment-related morbidity (TRMB) and non-inferior progression-free survival (PFS) in comparison to escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (eBEACOPP), a standard of ca

Automotive Industry Shifts Gears As Talent and Technology Take Center Stage3.6.2025 17:00:00 EEST | Press release

Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, today announced the results of the 10th annual “State of Smart Manufacturing Report: Automotive Edition.” The global study encompasses the responses of 130 leaders across automotive and tire manufacturers, original equipment manufacturers, engineering procurement companies and systems integrators across 15 countries, revealing a sector rapidly embracing change to stay competitive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603797393/en/ Rockwell Automation report shows manufacturers are leaning into AI, upskilling and innovation to overcome workforce and operational challenges. Workforce pressures have emerged as the most urgent challenge for automotive companies, signaling a significant shift from last year’s findings. At the same time, concerns around cybersecurity have declined, suggesti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye